Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Total Liabilities: 2009-2025

Historic Total Liabilities for Cytokinetics (CYTK) over the last 16 years, with Sep 2025 value amounting to $2.0 billion.

  • Cytokinetics' Total Liabilities rose 35.02% to $2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year increase of 35.02%. This contributed to the annual value of $1.5 billion for FY2024, which is 26.96% up from last year.
  • Per Cytokinetics' latest filing, its Total Liabilities stood at $2.0 billion for Q3 2025, which was up 22.79% from $1.6 billion recorded in Q2 2025.
  • In the past 5 years, Cytokinetics' Total Liabilities ranged from a high of $2.0 billion in Q3 2025 and a low of $509.2 million during Q1 2021.
  • Its 3-year average for Total Liabilities is $1.4 billion, with a median of $1.4 billion in 2024.
  • Data for Cytokinetics' Total Liabilities shows a peak YoY spiked of 88.75% (in 2022) over the last 5 years.
  • Quarterly analysis of 5 years shows Cytokinetics' Total Liabilities stood at $597.5 million in 2021, then skyrocketed by 87.91% to $1.1 billion in 2022, then increased by 7.84% to $1.2 billion in 2023, then climbed by 26.96% to $1.5 billion in 2024, then soared by 35.02% to $2.0 billion in 2025.
  • Its Total Liabilities was $2.0 billion in Q3 2025, compared to $1.6 billion in Q2 2025 and $1.5 billion in Q1 2025.